The therapy, delivered through a pressurised metered dose inhaler (pMDI), is indicated for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD). The launch brings together Lupin’s respiratory manufacturing capabilities and ERN’s established commercial presence in Spain.
The company said the partnership combines its global respiratory expertise and pMDI manufacturing capabilities with ERN’s reach and relationships in the Spanish healthcare market.
“The launch of Luforbec in Spain, following successful introductions in the UK and Germany, represents a key milestone in our partnership with ERN and reinforces our commitment to advancing global access to quality respiratory care,” said Thierry Volle, President, EMEA and Emerging Markets at Lupin.
David Solanes, Chief Executive Officer of LABORATORIOS ERN, said the collaboration would help bring an established respiratory therapy to patients and healthcare professionals in Spain while enabling the company to expand into a new therapeutic area.
Luforbec is a fixed-dose combination therapy comprising an inhaled corticosteroid and a long-acting beta2-agonist. It is prescribed for patients whose asthma is not adequately controlled through inhaled corticosteroids alone and is also used in the treatment of severe COPD in patients with a history of repeated exacerbations.
The announcement comes as Lupin continues to strengthen its global product portfolio and regulatory pipeline.
Last week, the company received approval from the US Food and Drug Administration (USFDA) for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar referencing Lucentis of Genentech. Lupin said Ranluspec is the only interchangeable biosimilar ranibizumab approved in the United States in both vial and pre-filled syringe formats.
The biosimilar is indicated for multiple retinal disorders, including wet age-related macular degeneration, diabetic macular oedema and diabetic retinopathy.
Separately, Lupin recently secured USFDA approval for Sodium Sulfate, Magnesium Sulfate and Potassium Chloride Tablets, used for colon cleansing prior to colonoscopy procedures. The company is the exclusive first-to-file applicant for the product and is eligible for 180 days of generic drug exclusivity in the United States.
According to IQVIA data cited by Lupin, the reference product generated annual US sales of approximately $132.8 million as of March 2026.
Also Read: Lupin’s US business to stay above $1 billion; biosimilars and specialty portfolio to drive growth
The company has also expressed confidence in the outlook for its US business. CNBC-TV18 reported on May 8 that Lupin expects its US operations to remain above the $1 billion revenue mark in FY27, supported by products including Tolvaptan, Mirabegron and a series of recent injectable launches.
Shares of Lupin were trading at ₹2,266.80 on the NSE in afternoon trade following the announcement.
